Overview
Metastatic malignant neoplasms involving the fundus of the stomach, predominantly adenocarcinoma, represent a challenging clinical scenario characterized by advanced disease at presentation. These cases often complicate the management approach, necessitating a multidisciplinary strategy that balances symptom palliation with potential survival benefits. Despite multimodal treatments including surgery, chemotherapy, and supportive care, prognosis remains guarded, with survival times often measured in months rather than years. Understanding the epidemiology, clinical presentation, diagnostic challenges, and evolving management strategies is crucial for optimizing patient outcomes. This guideline synthesizes current evidence to provide clinicians with a comprehensive framework for addressing metastatic gastric cancer.
Epidemiology
Gastric cancer, primarily adenocarcinoma, frequently presents with advanced or metastatic disease at the time of diagnosis, contributing significantly to its poor prognosis and relatively short survival times [PMID:31462229]. The SEER (Surveillance, Epidemiology, and End Results) database, which covers approximately 28% of the US population, underscores the importance of registry data in elucidating the epidemiology and treatment patterns of metastatic gastric cancer [PMID:31116140]. Studies utilizing such databases highlight that a substantial proportion of patients have distant metastases at initial presentation, often involving the liver, peritoneum, and lymph nodes, complicating therapeutic options and outcomes. The demographic trends indicate that incidence rates vary globally, with higher prevalence in East Asian populations, reflecting potential environmental and genetic factors influencing disease progression and metastasis [PMID:31462229].
Clinical Presentation
Patients with metastatic gastric cancer often present with a constellation of symptoms that reflect both local and systemic disease burden. Common clinical manifestations include gastrointestinal obstruction, tumor bleeding leading to anemia, and perforation, which can be life-threatening emergencies requiring urgent intervention [PMID:31116140]. Additionally, nonspecific symptoms such as weight loss, anorexia, and vague abdominal discomfort are frequently encountered. Interestingly, some patients may have normal levels of serum tumor markers like carcinoembryonic antigen (CEA) and CA19-9, which can complicate early diagnosis and monitoring [PMID:31462229]. The presence of metastases confined to a single site, particularly when serum tumor markers are within normal limits, tends to correlate with better outcomes following palliative interventions such as gastrectomy, emphasizing the importance of thorough staging and targeted therapy [PMID:31462229].
Diagnosis
Diagnosing metastatic gastric cancer at an advanced stage poses significant challenges due to the often subtle and nonspecific initial symptoms. Imaging modalities such as computed tomography (CT) scans and endoscopic ultrasonography (EUS) play pivotal roles in identifying primary tumors and metastatic spread. CT scans can reveal enlarged lymph nodes, liver metastases, and peritoneal involvement, while EUS provides detailed visualization of the gastric wall and regional lymph nodes, aiding in staging accuracy [PMID:31462229]. However, the complexity of metastatic patterns often necessitates a combination of imaging techniques alongside histopathological confirmation through endoscopic biopsies or surgical specimens. Despite advancements in diagnostic tools, the disease frequently progresses to advanced stages before definitive diagnosis, highlighting the need for heightened clinical suspicion and proactive screening in high-risk populations [PMID:31462229].
Management
Palliative Gastrectomy
The role of palliative gastrectomy in managing metastatic gastric cancer remains a focal point of clinical debate and evolving evidence. A systematic review and meta-analysis encompassing 14 studies with 3003 patients indicated that palliative gastrectomy significantly enhances overall survival compared to non-resectional treatments [PMID:31462229]. Key factors associated with improved outcomes include younger age, better preoperative nutritional status, fewer metastatic lymph nodes, and the integration of postoperative chemotherapy. Despite the REGATTA trial suggesting no survival advantage for gastrectomy, propensity score-matched analyses of the SEER database support the notion that gastrectomy, often combined with chemotherapy, can offer survival benefits in selected patients [PMID:31116140]. Specifically, palliative gastrectomy has been shown to be more effective than bypass surgery in alleviating symptoms such as obstruction and bleeding, thereby improving quality of life [PMID:31116140]. Meta-analyses further corroborate these findings, reporting a significantly higher 1-year overall survival in patients undergoing gastrectomy compared to conservative management (OR=4.9, 95% CI=3.2 to 7.5, p<0.0001) and non-resectional treatments (OR=2.6, 95% CI=1.7 to 4.3, p<0.0001) [PMID:24778009]. In a specific study involving 105 patients with stage IV gastric cancer, those who underwent palliative gastrectomy alongside adjuvant therapy achieved a mean survival of 16.3 months, markedly better than the 5.9 months observed in those receiving only systemic therapy [PMID:16369718].
Complications and Postoperative Outcomes
While palliative gastrectomy offers potential survival benefits, it is not without risks. Postoperative complications are a significant concern, with reported mortality rates ranging from 8.7% to 14% and morbidity rates from 27% to 33.3% [PMID:24778009; PMID:16369718]. These complications can include anastomotic leaks, infections, and nutritional deficiencies, with higher complication rates noted in Western populations compared to Asian patients, possibly reflecting differences in surgical techniques, patient selection criteria, or underlying health status [PMID:24778009]. Despite these challenges, recent studies indicate a trend towards improved surgical outcomes, with postoperative mortality rates below 5% in more contemporary analyses, suggesting advancements in surgical techniques and perioperative care [PMID:24778009].
Prognosis and Follow-Up
Predicting survival in patients with metastatic gastric cancer who undergo palliative gastrectomy involves integrating clinical, pathological, and demographic factors. Nomograms developed using the SEER database provide valuable tools for clinicians to estimate survival outcomes, aiding in clinical decision-making and patient counseling [PMID:31462229]. Kaplan-Meier analysis from various studies consistently shows significantly better survival in patients who receive palliative gastrectomy with adjuvant therapy, with log-rank tests indicating statistical significance (P = 0.01) [PMID:16369718]. Survival rates vary, with weighted analyses reporting 38% survival at 1 year and 17% at 2 years, reflecting notable differences between Asian and Western patient populations [PMID:24778009]. Regular follow-up is essential, encompassing clinical assessments, imaging studies, and monitoring of tumor markers to manage symptoms, detect recurrence, and adjust treatment strategies accordingly.
Key Recommendations
References
1 Ma T, Wu ZJ, Xu H, Wu CH, Xu J, Peng WR et al.. Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy. BMC cancer 2019. link 2 Li Q, Zou J, Jia M, Li P, Zhang R, Han J et al.. Palliative Gastrectomy and Survival in Patients With Metastatic Gastric Cancer: A Propensity Score-Matched Analysis of a Large Population-Based Study. Clinical and translational gastroenterology 2019. link 3 Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer research 2014. link 4 Saidi RF, ReMine SG, Dudrick PS, Hanna NN. Is there a role for palliative gastrectomy in patients with stage IV gastric cancer?. World journal of surgery 2006. link